<DOC>
	<DOCNO>NCT01696669</DOCNO>
	<brief_summary>Tumors Ewing sarcoma family ( ES ) affect child , adolescent young adult . The report incidence 0.6 case per million inhabitant every year . The peak incidence occur 10 20 year rarely diagnose beyond 30 . The ES severe disease progression-free survival 5 year 60 % case without metastasis deadly majority patient present metastasis . The ES consider systemic disease , despite receive adequate local treatment , 90 % patient deaths occur due disseminate disease . Combined therapy surgery , radiotherapy chemotherapy lead improvement prognosis , achieve survival 60 % series The MSKCC P6 protocol develop treatment high risk ES . In 2003 , Kolb et al . report MSKCC experience 4-years follow-up 68 patient include 1990 2001 . Following MSKCC P6 protocol , survival rate 82 % achieve patient without metastasis , superior achieve less intensive protocol . Following guideline MSKCC P6 protocol , 2002 modify treatment schedule create modify P6 protocol ( MP6 ) . GEIS intend develop MP6 clinical trial , could provide follow potential advantage current treatment : 1 . Lower total dose alkylating agent . 2 . Early cardioprotection dexrazoxane . 3 . Radiotherapy adjust initial response . 4 . Pilot trial combination Gemcitabine + Docetaxel high-risk patient .</brief_summary>
	<brief_title>Study Intensive Chemotherapy , Surgery Radiotherapy Treat Ewing 's Sarcoma Children Young Adults</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Patients Ewing 's Sarcoma molecular analysis perform one 2 reference laboratory study EWS gene rearrangement confirm RTPCR Hospital Sant Joan de Déu de Barcelona , fluorescence situ hybridization ( FISH ) Cancer Research Center Salamanca . Highrisk patient patient metastasis , patient primary tumor pelvis axial bone patient ( micro ) metastases bone marrow detect molecular study . The remain patient consider standard risk . Lung nodule identify CTscan diameter &gt; 5 mm consider metastatic . Nodules ≤ 5 mm biopsied . Age ≤ 40 year . Adequate renal hepatic function , define calculated creatinine clearance &gt; 60 ml/min , creatinine , total bilirubin , AST and/or ALT &lt; 1,5 time upper limit normal ( ULN ) . Normal cardiac function define echocardiography , ejection fraction ≥ 55 % . ECOG performance status 0 1 ( Appendix VIII ) . Informed consent form sign parent , guardian patient ( 18 year ) , prior start treatment . Patients childbearing age ( men woman ) must use effective contraceptive method study entry realization . Effective contraceptive method woman men extend 6 month stop treatment study . Pregnancy must exclude urine test ( negative pregnancy test ) prior inclusion study . Pregnancy breastfeed . Active infection severe concomitant disease . Severe psychiatric condition make impossible obtain sign informed consent form limit treatment compliance . Concurrent treatment experimental drug within 30 day prior study entry . History previous cancer diagnose treat past 5 year except basal cell carcinoma , cervical carcinoma situ superficial bladder cancer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Ewing 's Sarcoma</keyword>
	<keyword>P6 protocol MSKCC</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Docetaxel</keyword>
</DOC>